Allergan has diverse portfolio of products: Novasecta

John Rountree, partner at Novasecta, looks at anti-trust approvals and issues in the pharmaceutical sector, with specific comment on a potential deal between Teva and Allergan.

from Mergers and Acquisitions http://ift.tt/1WjZIDr